尼达尼治疗特发性肺纤维化患者的体重减轻

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Hiromi Tomioka, Masaaki Iwabayashi, Makoto Yokota, Rika Hashimoto, Hisanori Amimoto
{"title":"尼达尼治疗特发性肺纤维化患者的体重减轻","authors":"Hiromi Tomioka,&nbsp;Masaaki Iwabayashi,&nbsp;Makoto Yokota,&nbsp;Rika Hashimoto,&nbsp;Hisanori Amimoto","doi":"10.1016/j.pupt.2023.102213","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Nintedanib is approved for the </span>treatment of </span>idiopathic pulmonary fibrosis<span><span><span><span> (IPF). Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF. Here, we report a single-center, retrospective cohort study to assess </span>body weight changes during nintedanib therapy </span>in patients with IPF. Sixty-one patients treated with nintedanib for &gt;6 months were included (45 males, mean age ± standard deviation 73.1 ± 7.4 years). Baseline body weight and </span>body mass index were 60.1 ± 12.0 kg and 23.2 ± 3.5 kg/m</span></span><sup>2</sup><span>, respectively. Mean weight loss during the first 6 months of nintedanib treatment was significant (−3.2 ± 3.4 kg, p &lt; 0.0001) with Common Terminology Criteria for Adverse Events (CTCAE) grades 0,1,2 or 3 of 30, 17, 13 and 1, respectively. Pulmonary function test<span> records 6 months before nintedanib administration were available in a subset of patients (n = 40). Significant differences in weight change over the 6 months before-vs-after nintedanib administration were also observed in these patients [mean differences −2.5 ± 3.4 kg, 95% confidence interval (CI) −3.6, −1.4, p &lt; 0.0001]. Multivariate analysis showed that only baseline body weight was significantly associated with weight loss of CTCAE grade ≧2 (odds ratio 0.921, 95% CI 0.854, 0.994). Median follow-up from starting nintedanib was 34.8 months. There was a significant difference in overall survival between patients with CTCAE grade ≧2-vs-grade&lt;2 (median survival of 25.5 months and 55.2 months, p = 0.014). In the model adjusting for age, sex and lung function, weight loss CTCAE grade ≧2 was an independent predictor for all-cause mortality (hazard ratio 2.448, 95% CI 1.080–5.551). In conclusion, weight loss is an important issue for the management of patients with IPF treated with nintedanib.</span></span></p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis\",\"authors\":\"Hiromi Tomioka,&nbsp;Masaaki Iwabayashi,&nbsp;Makoto Yokota,&nbsp;Rika Hashimoto,&nbsp;Hisanori Amimoto\",\"doi\":\"10.1016/j.pupt.2023.102213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>Nintedanib is approved for the </span>treatment of </span>idiopathic pulmonary fibrosis<span><span><span><span> (IPF). Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF. Here, we report a single-center, retrospective cohort study to assess </span>body weight changes during nintedanib therapy </span>in patients with IPF. Sixty-one patients treated with nintedanib for &gt;6 months were included (45 males, mean age ± standard deviation 73.1 ± 7.4 years). Baseline body weight and </span>body mass index were 60.1 ± 12.0 kg and 23.2 ± 3.5 kg/m</span></span><sup>2</sup><span>, respectively. Mean weight loss during the first 6 months of nintedanib treatment was significant (−3.2 ± 3.4 kg, p &lt; 0.0001) with Common Terminology Criteria for Adverse Events (CTCAE) grades 0,1,2 or 3 of 30, 17, 13 and 1, respectively. Pulmonary function test<span> records 6 months before nintedanib administration were available in a subset of patients (n = 40). Significant differences in weight change over the 6 months before-vs-after nintedanib administration were also observed in these patients [mean differences −2.5 ± 3.4 kg, 95% confidence interval (CI) −3.6, −1.4, p &lt; 0.0001]. Multivariate analysis showed that only baseline body weight was significantly associated with weight loss of CTCAE grade ≧2 (odds ratio 0.921, 95% CI 0.854, 0.994). Median follow-up from starting nintedanib was 34.8 months. There was a significant difference in overall survival between patients with CTCAE grade ≧2-vs-grade&lt;2 (median survival of 25.5 months and 55.2 months, p = 0.014). In the model adjusting for age, sex and lung function, weight loss CTCAE grade ≧2 was an independent predictor for all-cause mortality (hazard ratio 2.448, 95% CI 1.080–5.551). In conclusion, weight loss is an important issue for the management of patients with IPF treated with nintedanib.</span></span></p></div>\",\"PeriodicalId\":20799,\"journal\":{\"name\":\"Pulmonary pharmacology & therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary pharmacology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094553923000251\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553923000251","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

尼替达尼被批准用于治疗特发性肺纤维化(IPF)。在尼替达尼治疗期间,体重减轻被认为是一种不良事件,是一种常见的并发症,可作为IPF的预后指标。在此,我们报告了一项单中心回顾性队列研究,以评估尼替达尼治疗IPF患者期间的体重变化。61名患者接受宁替达尼治疗>;纳入6个月(男性45例,平均年龄±标准差73.1±7.4岁)。基线体重和体重指数分别为60.1±12.0 kg和23.2±3.5 kg/m2。尼替达尼治疗前6个月的平均体重减轻显著(−3.2±3.4 kg,p<0.0001),不良事件通用术语标准(CTCAE)等级分别为0,1,2或3/30、17、13和1。在一部分患者(n=40)中,可以获得给药宁替达尼前6个月的肺功能测试记录。这些患者在服用尼替达尼前后6个月的体重变化也存在显著差异[平均差异-2.5±3.4 kg,95%置信区间(CI)-3.6,-1.4,p<;0.0001]。多变量分析显示,只有基线体重与CTCAE≥2级的体重减轻显著相关(比值比0.921,95%CI 0.854,0.994)。从开始服用尼替达尼开始的中位随访时间为34.8个月。CTCAE分级≥2-vs-grade<;2(中位生存期为25.5个月和55.2个月,p=0.014)。在调整年龄、性别和肺功能的模型中,体重减轻CTCAE分级≥2是全因死亡率的独立预测因素(危险比2.448,95%CI 1.080–5.551)。总之,体重减轻是用尼替达尼治疗的IPF患者管理的一个重要问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis

Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF. Here, we report a single-center, retrospective cohort study to assess body weight changes during nintedanib therapy in patients with IPF. Sixty-one patients treated with nintedanib for >6 months were included (45 males, mean age ± standard deviation 73.1 ± 7.4 years). Baseline body weight and body mass index were 60.1 ± 12.0 kg and 23.2 ± 3.5 kg/m2, respectively. Mean weight loss during the first 6 months of nintedanib treatment was significant (−3.2 ± 3.4 kg, p < 0.0001) with Common Terminology Criteria for Adverse Events (CTCAE) grades 0,1,2 or 3 of 30, 17, 13 and 1, respectively. Pulmonary function test records 6 months before nintedanib administration were available in a subset of patients (n = 40). Significant differences in weight change over the 6 months before-vs-after nintedanib administration were also observed in these patients [mean differences −2.5 ± 3.4 kg, 95% confidence interval (CI) −3.6, −1.4, p < 0.0001]. Multivariate analysis showed that only baseline body weight was significantly associated with weight loss of CTCAE grade ≧2 (odds ratio 0.921, 95% CI 0.854, 0.994). Median follow-up from starting nintedanib was 34.8 months. There was a significant difference in overall survival between patients with CTCAE grade ≧2-vs-grade<2 (median survival of 25.5 months and 55.2 months, p = 0.014). In the model adjusting for age, sex and lung function, weight loss CTCAE grade ≧2 was an independent predictor for all-cause mortality (hazard ratio 2.448, 95% CI 1.080–5.551). In conclusion, weight loss is an important issue for the management of patients with IPF treated with nintedanib.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信